Editas Medicine Inc
NASDAQ:EDIT
Editas Medicine Inc
Selling, General & Administrative
Editas Medicine Inc
Selling, General & Administrative Peer Comparison
Competitive Selling, General & Administrative Analysis
Latest Figures & CAGR of Competitors
Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Editas Medicine Inc
NASDAQ:EDIT
|
Selling, General & Administrative
-$69.7m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Selling, General & Administrative
-$12.7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-9%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Selling, General & Administrative
-$6.1B
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-13%
|
|
Amgen Inc
NASDAQ:AMGN
|
Selling, General & Administrative
-$6.2B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-2%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Selling, General & Administrative
-$1.1B
|
CAGR 3-Years
-14%
|
CAGR 5-Years
-15%
|
CAGR 10-Years
-12%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Selling, General & Administrative
-$2.6B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-23%
|
See Also
What is Editas Medicine Inc's Selling, General & Administrative?
Selling, General & Administrative
-69.7m
USD
Based on the financial report for Dec 31, 2023, Editas Medicine Inc's Selling, General & Administrative amounts to -69.7m USD.
What is Editas Medicine Inc's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 5Y
-5%
Over the last year, the Selling, General & Administrative growth was 1%. The average annual Selling, General & Administrative growth rates for Editas Medicine Inc have been -1% over the past three years , -5% over the past five years .